We investigated the molecular mechanisms underlying the oncogenic activity of aberrantly activated FGFR3 in bladder carcinomas, by studying the MGH‐U3 and RT112 cell lines. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.